Physician profile
Lin Fu
NPI 1659979938
$2,898.58
in general payments reported to CMS, 2019-2025
31 companies · $582 in 2025
The $582 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $437 · 2022: $573 · 2023: $726 · 2024: $581 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $499.96 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $315.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $304.85 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $250.05 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $171.39 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Pfizer INC. | $113.99 | 2021-2025 | |
| Ucb, INC. | $106.61 | 2021-2023 | Nayzilam |
| Teva Pharmaceuticals USA, INC. | $96.27 | 2022-2024 | Austedo Xr, Austedo |
| Novo Nordisk INC | $91.89 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $90.49 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $84.24 | 2021-2022 | |
| Amgen INC. | $83.66 | 2021-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $72.28 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $68.81 | 2024-2025 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.20 | 2025 | |
| Biogen, INC. | $49.59 | 2021-2022 | |
| Lundbeck LLC | $41.86 | 2024-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $31.80 | 2023 | Nuplazid |
| Janssen Pharmaceuticals, INC | $28.03 | 2023 | Xarelto |
| Dexcom, INC. | $27.66 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $22.62 | 2023 | Gattex |
| Sumitomo Pharma America, INC. | $22.45 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $20.63 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.46 | 2024 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $19.25 | 2022 | |
| Kaleo, INC. | $18.49 | 2022 | |
| Corcept Therapeutics | $17.74 | 2025 | Korlym |
| Aimmune Therapeutics, INC. | $16.47 | 2025 | Zenpep |
| Endo Pharmaceuticals INC. | $16.28 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.